Global Diacerein Market Size, Share, and Trends Analysis Report, By Type (Combination Drugs and Prescribed Drugs), By Application (Arthritis, Musculoskeletal Pain, Bullous Epidermolysis, Pemphigus, and Pemphigoid), Forecast (2022-2028)

The global diacerein market is anticipated to grow at a CAGR of nearly 3.5% during the forecast period (2022-2028). Diacerein which is also known as diacetylrhein is a slow-acting medicine of the class used to treat joint diseases such as osteoarthritis which is swelling and pain in the joints.. Diacerein is a medicine that is used to treat joint diseases such as osteoarthritis and many more. Diacerein works by blocking the actions of a protein involved in the inflammation and destruction of that plays a role in the development of symptoms of degenerative joint diseases such as

However, the side effects of diacerein treatment such as gastrointestinal symptoms including soft stools and diarrhea can be the restraining factor for the market growth. Some diacerein drugs that are available on the market are Abrocitinib, Acebutolol, Acenocoumarol, and Acetaminophen. Diacerein’s active metabolite rhein reduces cartilage destruction by decreasing the expression of matrix metalloproteinase (MMP)-1 and -3 as well as upregulating tissue inhibitors of matrix metalloproteinases which serve to reduce the activity of several matrix metalloproteinases. Rhein is an anthraquinone metabolite of rheinanthrone and senna glycoside is present in many medicinal plants including rheum palmatum, cassia tora, polygonum multiflorum, and aloe barbadensis.

global diacerein market is segmented based on the type and application. Based on the application, the market is sub-segmented into arthritis, musculoskeletal pain, bullae epidermolysis, pemphigus, and pemphigoid. Arthritis is caused by inflammation of the joints. Osteoarthritis usually comes with age and most often affects the fingers, knees, and hips. Sometimes osteoarthritis follows a joint injury. Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic, and pro-anabolic properties on cartilage and synovial membrane. It has also recently been shown to have protective effects against subchondral bone remodeling. Epidermolysis bullosa (EB) is a group of rare medical conditions that result in easy blistering of the skin and mucous membranes. Blisters occur with minor trauma or friction and are painful. Diacerein, a rhein prodrug, and anthraquinone have been shown to reduce the expression of K14 and inhibit IL-1 converting enzymes. In clinical trials, topical 1% diacerein was shown to be an effective and safe, non-invasive treatment for patients suffering from EBS.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Novartis International AG, Glenmark Pharmaceuticals Ltd., and Cadila Pharmaceuticals, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?

Global Diacerein Market Report by Segment

By Type

• Combination Drugs
• Prescribed Drugs

By Application

• Arthritis
• Musculoskeletal Pain
• Bullous Epidermolysis
• Pemphigus
• Pemphigoid

Global Diacerein Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa